Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29696727 | 0.96 | CASP3 (0.47) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL19602467 | 0.90 | MDM4 (0.51) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29696744 | 0.89 | CASP3 (0.54) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL30517410 | 0.88 | CASP3 (0.45) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL27719894 | 0.88 | CASP3 (0.48) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL19134428 | 0.87 | CASP3 (0.50) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL31149057 | 0.87 | CASP3 (0.50) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL29477082 | 0.86 | CASP3 (0.47) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL119043 | 0.84 | CASP3 (0.57) | CASP3MDM4TP53KMT2AEPHX2 | |
| SCHEMBL31720042 | 0.84 | KMT2A (0.54) | CASP3MDM4TP53KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CASP3 343/4885MDM4 3559/4885TP53 2654/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CASP3 343/4885MDM4 3559/4885TP53 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.